Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Security

Maze Therapeutics, Inc. Common Stock · MAZE

MAZENASDAQCommon stockCurrentCIK 1842295Updated Nov 17, 2026

Company: Maze Therapeutics, Inc. →

MAZE price & chart

Provider market data

Loading TradingView…

NASDAQ:MAZE on TradingView ↗

TradingView · Data may be delayed

About the company

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X.

8-K · 2026-11-09 · 0001193125-26-453590

Company description from the cited filing.

Financials

FY 2025 · USD
Revenue— · FY 2025
Net income-131,120,000USD · FY 2025
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

Operating income-142,899,000USD · FY 2025
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

Diluted EPS-3.05USD per share · FY 2025
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

balance sheet · annual statements
Line itemQ3 2025Q3 2024Q2 2026Q2 2025Q2 2024Q1 2026Q1 2025Q1 2024FY 2025FY 2024
ASSETS
AssetsUSD422,058,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—531,625,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

303,519,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—419,710,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

332,840,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—397,127,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

240,542,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Property, Plant and Equipment, NetUSD5,538,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—4,391,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

6,006,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—4,682,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

6,314,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—5,044,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

6,668,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Current assets:
Cash and Cash Equivalents, at Carrying ValueUSD316,773,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

149,607,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2024-09-30

202,643,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

264,541,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2025-06-30

175,065,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2024-06-30

198,766,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

294,374,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2025-03-31

30,023,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2024-03-31

189,247,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

196,812,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Assets, CurrentUSD391,302,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—420,423,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

271,150,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—379,779,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

299,707,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—349,717,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

201,671,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Prepaid Expense and Other Assets, CurrentUSD7,367,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—9,336,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

6,609,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—7,397,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

5,333,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—7,800,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

4,859,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Operating Lease, Right-of-Use AssetUSD20,920,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—18,442,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

21,707,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—19,285,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

22,483,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—20,116,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

23,250,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Other Assets, NoncurrentUSD3,209,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—3,460,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

3,567,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—4,320,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

3,247,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—3,048,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

7,865,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

LIABILITIES AND EQUITY
LiabilitiesUSD42,622,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—78,501,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

41,281,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—78,009,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

40,772,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—42,161,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

43,638,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Stockholders’ equity:
Preferred Stock, Value, IssuedUSD0
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—0
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

0
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—0
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

——0
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

0
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Common Stock, Value, IssuedUSD48,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—56,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

44,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—50,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

44,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—49,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

2,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Additional Paid in CapitalUSD834,298,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—1,011,985,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

687,086,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—855,541,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

683,237,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—844,354,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

47,242,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Retained Earnings (Accumulated Deficit)USD-454,979,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—-558,482,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

-424,892,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—-513,755,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

-391,213,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—-489,547,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

-358,427,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Stockholders' Equity Attributable to ParentUSD379,436,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—453,124,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

262,238,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—341,701,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

292,068,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—354,966,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

-311,183,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Liabilities and EquityUSD422,058,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—531,625,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

303,519,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—419,710,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

332,840,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—397,127,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

240,542,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Current liabilities:
Liabilities, CurrentUSD22,112,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—22,961,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

19,900,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—21,236,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

18,617,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—22,556,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

20,673,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Operating Lease, Liability, CurrentUSD4,764,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—4,883,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

4,718,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—4,838,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

4,674,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—4,795,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

4,632,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Accounts Payable, CurrentUSD2,918,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—2,212,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

3,666,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—4,013,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

2,404,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—1,794,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

1,939,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Operating Lease, Liability, NoncurrentUSD19,419,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—16,580,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

20,291,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—17,552,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

21,149,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—18,511,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

21,996,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Other Liabilities, NoncurrentUSD1,091,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

——1,090,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

As of 2025-06-30

—388,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

1,006,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

As of 2025-03-31

—1,094,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

969,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Additional Financial Items
AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD69,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—-435,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

——-135,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

——110,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

—
Accounts Receivable, after Allowance for Credit Loss, Current——————
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

————
Cash, Cash Equivalents, and Short-term Investments—
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

—————
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

————
Long-term Debt, Excluding Current Maturities———
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

———
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

————
Long-term Debt, Current Maturities———
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

———
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

————
Long-term Debt, Excluding Current Maturities———
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

———
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

————

Lines labelled “Derived” are calculated from reported figures.

cash flow · annual statements
Line itemQ4 2025Q4 2024Q3 2025Q3 2024Q2 2026Q2 2025Q1 2026Q1 2025FY 2025FY 2024
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD——————-24,208,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

-32,786,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

-131,120,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

52,231,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Adjustments to reconcile net income to net cash provided by operating activities:
Share-based Payment Arrangement, Noncash ExpenseUSD——————7,109,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

3,226,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

16,400,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

9,646,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Changes in operating assets and liabilities:
Increase (Decrease) in Accounts PayableUSD——————2,212,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

579,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

-27,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

-204,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Net Cash Provided by (Used in) Operating ActivitiesUSD——————-39,113,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

-29,516,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

-111,940,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

75,954,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Cash flows from investing activities:
Net Cash Provided by (Used in) Investing ActivitiesUSD——————6,275,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

-299,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

-170,962,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

-1,147,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Payments to Acquire Property, Plant, and EquipmentUSD——————93,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

299,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

794,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

1,147,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Cash flows from financing activities:
Net Cash Provided by (Used in) Financing ActivitiesUSD——————42,357,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

127,378,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

275,337,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

92,847,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD——317,862,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

150,695,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2024-09-30

203,731,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2026-06-30

265,630,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

As of 2025-06-30

199,854,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

295,463,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2025-03-31

190,335,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2025-12-31

197,900,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

As of 2024-12-31

Supplemental disclosure of cash flow information:
Income Taxes Paid, NetUSD—————————1,230,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Additional Financial Items
Share-based Payment Arrangement, ExpenseUSD——3,864,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

2,343,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

9,187,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

3,237,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

7,109,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

3,226,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

16,400,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

9,646,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

DepreciationUSD——————444,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

684,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

2,403,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

3,297,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

General and Administrative ExpenseUSD——7,775,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

6,872,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

13,095,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

8,366,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

12,405,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

7,821,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

34,451,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

26,418,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Income Tax Expense (Benefit)USD——0
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

-279,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

—0
Source

10-Q · 2025-08-12 · 0000950170-25-107306

2025-04-01 to 2025-06-30

——0
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

1,172,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Marketable Securities, Unrealized Gain (Loss)USD——69,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

—-300,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

—-245,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

—110,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

—
Net Income (Loss) Attributable to ParentUSD——-30,087,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

-24,752,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

-44,727,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

-33,679,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

-24,208,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

-32,786,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

-131,120,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

52,231,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Net Income (Loss) Available to Common Stockholders, BasicUSD——-30,087,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

-24,752,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

—-33,679,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

2025-04-01 to 2025-06-30

——-131,120,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

3,405,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Operating ExpensesUSD——32,965,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

26,729,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

48,035,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

36,474,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

46,553,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

35,401,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

142,899,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

109,914,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Operating Lease, ExpenseUSD——————831,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

767,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

3,134,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

2,889,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Proceeds from Stock Options ExercisedUSD——————4,079,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

126,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

5,561,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

733,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Amortization of Debt Issuance Costs and Discounts———————
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

———
Cash, Cash Equivalents, and Short-term Investments———
Source

10-Q · 2025-11-06 · 0001193125-25-269689

As of 2025-09-30

————
Source

10-Q · 2026-05-12 · 0001193125-26-219430

As of 2026-03-31

———
InterestExpenseNonoperating—————
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

——
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

———
Other Nonoperating Income (Expense)—————
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

—
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

—
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

—
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

——

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemQ4 2025Q4 2024Q3 2025Q3 2024Q2 2026Q2 2025Q1 2026Q1 2025FY 2025FY 2024
Total RevenueUSD———2,500,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

—0
Source

10-Q · 2025-08-12 · 0000950170-25-107306

2025-04-01 to 2025-06-30

20,000,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

——167,500,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Operating Income (Loss)USD——-32,965,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

-24,229,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

-48,035,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

-36,474,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

-26,553,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

-35,401,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

-142,899,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

57,586,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD——-30,087,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

-25,031,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

—-33,679,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

2025-04-01 to 2025-06-30

—-32,786,000
Source

10-Q · 2025-05-14 · 0000950170-25-071375

2025-01-01 to 2025-03-31

-131,120,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

53,403,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Income Tax Expense (Benefit)USD——0
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

-279,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

—0
Source

10-Q · 2025-08-12 · 0000950170-25-107306

2025-04-01 to 2025-06-30

——0
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

1,172,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Net Income (Loss) Attributable to ParentUSD——-30,087,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

-24,752,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

-44,727,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

-33,679,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

-24,208,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

-32,786,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

-131,120,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

52,231,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Earnings Per Share, BasicUSD per share——-0.66
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

-10.25
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

-0.76
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

-0.77
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

-0.45
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

-1.15
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

-3.05
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

1.42
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Earnings Per Share, DilutedUSD per share——-0.66
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

-10.25
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

-0.76
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

-0.77
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

-0.45
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

-1.15
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

-3.05
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

1.25
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Weighted Average Number of Shares Outstanding, Basicshares——45,779,577
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

2,415,897
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

58,995,934
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

43,797,421
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

53,897,216
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

28,628,430
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

42,976,024
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

2,396,094
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Weighted Average Number of Shares Outstanding, Dilutedshares——45,779,577
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

2,415,897
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

58,995,934
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

43,797,421
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

53,897,216
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

28,628,430
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

42,976,024
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

2,730,299
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Additional Financial Items
General and Administrative ExpenseUSD——7,775,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

6,872,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

13,095,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

8,366,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

12,405,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

7,821,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

34,451,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

26,418,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Interest and Other IncomeUSD——2,878,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

1,846,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

4,239,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

2,795,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

3,211,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

2,615,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

11,779,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

4,654,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Net Income (Loss) Available to Common Stockholders, BasicUSD——-30,087,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

-24,752,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

—-33,679,000
Source

10-Q · 2025-08-12 · 0000950170-25-107306

2025-04-01 to 2025-06-30

——-131,120,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

3,405,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Operating ExpensesUSD——32,965,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

26,729,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

48,035,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

36,474,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

46,553,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

35,401,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

142,899,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

109,914,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Operating Lease, ExpenseUSD——————831,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

767,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

3,134,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

2,889,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Research and Development ExpenseUSD——25,190,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2025-07-01 to 2025-09-30

19,857,000
Source

10-Q · 2025-11-06 · 0001193125-25-269689

2024-07-01 to 2024-09-30

34,940,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

28,108,000
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

34,148,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

27,580,000
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

108,448,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2025-01-01 to 2025-12-31

83,496,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD—————————-33,854,000
Source

10-K · 2026-03-25 · 0001193125-26-122778

2024-01-01 to 2024-12-31

Other Nonoperating Income (Expense)—————
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

—
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2025-04-01 to 2025-06-30

—
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

—
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2025-01-01 to 2025-03-31

——
Interest Expense (non-operating)—————
Source

10-Q · 2026-08-11 · 0001193125-26-344903

2026-04-01 to 2026-06-30

——
Source

10-Q · 2026-05-12 · 0001193125-26-219430

2026-01-01 to 2026-03-31

———

Lines labelled “Derived” are calculated from reported figures.

Offerings

Registration 333-290935

POS AM · 2026-05-12 · 0001193125-26-219386

Terms from the governing filing for this registration; not a claim that the offering is open today.

Registration 333-293206

S-3ASR · 2026-02-04 · 0001193125-26-037831

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

maze-ex99_1.htm · 8-K · 2026-11-09

Exhibit 99.1 Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027 Enrollment ongoing in Phase 2 CIPheR trial of MZE782 in PKU; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $477 million in cash, cash equivalents and marketable securities as of September 30, 2026 supports expected r…

8-K · 2026-11-09 · 0001193125-26-453590

Read attachment ↗
d135740dex991.htm · 8-K · 2026-08-17

EX-99.1 2 d135740dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Maze Therapeutics Announces Appointments to Its Board of Directors August 13, 2026 Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm. D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precis…

8-K · 2026-08-17 · 0001193125-26-354092

Read attachment ↗
maze-ex99_1.htm · 8-K · 2026-08-11

EX-99.1 2 maze-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $495 million in cash, cash equivalents and m…

8-K · 2026-08-11 · 0001193125-26-344878

Read attachment ↗
maze-ex99_1.htm · 8-K · 2026-05-12

EX-99.1 2 maze-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026 or early 2027 Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD on track to initiate in 2026 Strong balance sheet with $528 m…

8-K · 2026-05-12 · 0001193125-26-219398

Read attachment ↗
d115741dex41.htm · 8-K · 2026-04-22

EX-4.1 3 d115741dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: April [ ], 2026 ───────────────────────────────────────────────────────────── Maze Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its registered assigns …

8-K · 2026-04-22 · 0001193125-26-170701

Read attachment ↗
d115741dex991.htm · 8-K · 2026-04-22

EX-99.1 5 d115741dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Maze Therapeutics Announces $150 Million Registered Offering SOUTH SAN FRANCISCO, April 21, 2026 - Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common…

8-K · 2026-04-22 · 0001193125-26-170701

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.